The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Open accessAbstract
After the first attachment of virus to the cell surface through a primary receptor, efficient entry of virus requires the presence of a coreceptor. For adeno-associated virus type 2 (AAV2) infection, heparan sulfate proteoglycan is supposed as the primary receptor, and αvβ5 integrin and FGFR1 are reported to act as coreceptors. In this study, we were able to demonstrate that hepatocyte growth factor receptor, c-Met, is also a coreceptor for AAV2 infection. AAV2-mediated transgene analyses revealed that c-Met expression significantly up-regulated transgene expression without increasing AAV2 cell binding. Moreover, a viral overlay assay elucidated the physical interaction between AAV2 and the β subunit of c-Met. These data suggest that c-Met plays the role of coreceptor for AAV2 infection by facilitating AAV2 internalization into the cytoplasm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The early steps of AAV infection involve attachment to a variety of cell surface receptors such as HSPG, FGFR, αvβ5 integrin, and hepatocyte growth factor receptor (c-Met) (Fig. 8I) (9, 25, 31, 39, 40), followed by clathrin-dependent endocytosis (Fig.8II).”
From Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps (2005) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Woude, G. F. V., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,226
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,409
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Woude, G. F. V. (1984) · Nature · doi:10.1038/311029a0 · Cited by 1,000
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Emerging Multipotent Aspects of Hepatocyte Growth Factor
Matsumoto, K., & Nakamura, T. (1996) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021283 · Cited by 666
Self-citationPurification and subunit structure of hepatocyte growth factor from rat platelets
Nakamura, T., Nawa, K., Ichihara, A., Kaise, N., & Nishino, T. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80475-1 · Cited by 548
Self-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“by on January 25, 2010 jvi.asm.org Downloaded from ( 2 ).”
Background
Cited by
Sorted by citations
Items 101–200 of 245
Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction
Hirosue, S., Senn, K., Clément, N., Nonnenmacher, M. E., Gigout, L. I., Linden, R. M., & Weber, T. (2007) · Virology · doi:10.1016/j.virol.2007.05.009 · Cited by 35
“This process begins with the binding of rAAV2 to its primary receptor heparansulfate proteoglycan (Summerford and Samulski, 1998) and one of several possible co-receptors (Asokan et al., 2006; Kashiwakura et al., 2005; Qing et al., 1999; Qiu and Brown, 1999; Qiu et al., 2000; Qiu, Mizukami, and Brown, 1999; Summerford…”
BackgroundWatanabe, M., Kashiwakura, Y., Kusumi, N., Tamayose, K., Nasu, Y., Nagai, A., Shimada, T., Daida, H., & Kumon, H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302463 · Cited by 34
Self-citationKlugmann, M., & Szumlinski, K. K. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830c369f · Cited by 34
“Heparan sulphate proteoglycan is the primary receptor for AAV2 (Summerford and Samulski, 1998), whereas human fibroblast growth factor receptor 1 (Qing et al., 1999), aVb5 integrin (Summerford et al., 1999) and hepatocyte growth factor (Kashiwakura et al., 2005) act as coreceptors.”
BackgroundLiu, X., Luo, M., Trygg, C., Yan, Z., Lei-Butters, D. C. M., Smith, C. I., Fischer, A. C., Munson, K. B., Guggino, W. B., Bunnell, B. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300277 · Cited by 32
Su, W., Kang, J., Sopher, B. L., Gillespie, J., Aloi, M. S., Odom, G. L., Hopkins, S., Case, A., Wang, D. B., Chamberlain, J. S., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13081 · Cited by 37
“1999), hepatocyte growth factor receptor (Kashiwakura et al. 2005), aVb1 integrin (Asokan et al.”
BackgroundBattling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches
Mijanović, O., Branković, A., Borovjagin, A. V., Butnaru, D. V., Bezrukov, E. A., Sukhanov, R. B., Shpichka, A. I., Timashev, P. S., & Ulasov, I. V. (2020) · Viruses · doi:10.3390/v12040460 · Cited by 32
“The broad tropism of AAV is owed to the diversity of its natural cell-binding targets, such as primary receptors heparan sulfate proteoglycan (HSPG) [75] and/or N-glycans with terminal galactose [48], and several known co-receptors, such as fibroblast growth factor (FGF) receptor 1 [76], platelet-derived growth factor…”
BackgroundOrganoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 35
A role for adeno-associated viral vectors in gene therapy
Coura, R., & Nardi, N. B. (2008) · Genetics and Molecular Biology · doi:10.1590/s1415-47572008000100001 · Cited by 32
“…stimulus for viral internalization, which, additionally, requires binding to co-receptors, such as αvβ5 integrin heterodimers (Summerford et al., 1999), fibroblast growth factor receptor type 1 (Qing et al., 1999) and the hepatocyte growth factor receptor, c-Met (Kashiwakura et al., 2005).”
BackgroundDenard, J., Marolleau, B., Jenny, C., Rao, T. N., Fehling, H. J., Voit, T., & Svinartchouk, F. (2013) · Journal of Virology · doi:10.1128/jvi.01813-13 · Cited by 31
Díaz‐Lezama, N., Wu, Z., Adán‐Castro, E., Arnold, E., Vázquez‐Membrillo, M., Zamarripa, D. A., Ledesma-Colunga, M. G., Moreno-Carranza, B., de la Escalera, G. M., Colosi, P., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.135 · Cited by 29
AAV2-Mediated Transduction of the Mouse Retina After Optic Nerve Injury
Nickells, R. W., Schmitt, H. M., Maes, M. E., & Schlamp, C. L. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22634 · Cited by 28
Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Hughes, A., Jessup, C. F., Drogemuller, C., Mohanasundaram, D., Milner, C. R., Rojas, D., Russ, G. R., & Coates, P. T. H. (2010) · Current Diabetes Reviews · doi:10.2174/157339910793360897 · Cited by 28
“The ability of AAV to transduce a given cell type depends on the presence of membrane-associated heparan sulfate proteoglycan (HSPG) receptors [39] and co-receptors including v 5 integrin heterodimers, fibroblast growth factor receptor type 1 and c-met [40-43].”
BackgroundPolarized AAVR expression determines infectivity by AAV gene therapy vectors
Hamilton, B. A., Li, X., Pezzulo, A. A., Alaiwa, M. H. A., & Zabner, J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0078-3 · Cited by 28
Functional Analysis of the Putative Integrin Recognition Motif on Adeno-associated Virus 9
Shen, S., Berry, G. E., Rivera, R. M. C., Cheung, R., Troupes, A. N., Brown, S. M., Kafri, T., & Asokan, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608281 · Cited by 26
“For instance, the FGF receptor is exploited by AAV2 (11), whereas the hepatocyte growth factor receptor/C-Met appears to be utilized by both AAV2 and AAV3 (12, 13).”
BackgroundBAAV Transcytosis Requires an Interaction with β-1-4 Linked- Glucosamine and gp96
Pasquale, G. D., Kaludov, N. K., Agbandje‐McKenna, M., & Chiorini, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009336 · Cited by 27
“receptors, the integrins aVb5 and a5b1, fibroblast growth factor receptor and hepatocyte growth factor receptor, for cellular recognition and internalization [35–38].”
BackgroundReceptor Switching in Newly Evolved Adeno-associated Viruses
Havlik, L. P., Das, A., Mietzsch, M., Oh, D. K., Ark, J., McKENNA, R. V., Agbandje‐McKenna, M., & Asokan, A. (2021) · Journal of Virology · doi:10.1128/jvi.00587-21 · Cited by 25
Kaminsky, P., Keiser, N. W., Yan, Z., Lei-Butters, D. C. M., & Engelhardt, J. F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.295 · Cited by 22
rAAV-Mediated Cochlear Gene Therapy: Prospects and Challenges for Clinical Application
Blanc, F., Mondain, M., Bemelmans, A., Affortit, C., Puel, J., & Wang, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020589 · Cited by 21
“AAV2 uses αVβ5 integrins [29], fibroblast growth factor receptor 1 [30], hepatocyte growth factor receptor [31], αVβ1 integrin [32], and a laminin receptor [33].”
BackgroundBuscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
“For AAV2, the most widely studied AAV, the hepatocyte growth factor receptor c-Met [75], αVβ5 integrin [76] and fibroblast growth factor receptor 1 (FGFR1) [77] were demonstrated to increase AAV infectiosity and proposed as co-receptors.”
BackgroundAbulimiti, A., Lai, M. S., & Chang, R. C. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111549 · Cited by 23
Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing
de Alencastro, G., Pekrun, K., Valdmanis, P. N., Tiffany, M. R., Xu, J., & Kay, M. A. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.339 · Cited by 22
The use of recombinant adeno‐associated virus for skeletal gene therapy
Dai, J., & Rabie, A. B. M. (2007) · Orthodontics and Craniofacial Research · doi:10.1111/j.1601-6343.2007.00381.x · Cited by 22
High-throughput Screening and Biophysical Interrogation of Hepatotropic AAV
Murphy, S. L., Bhagwat, A. S., Edmonson, S. A., Zhou, S., & High, K. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.210 · Cited by 20
Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
Kuklik, J., Michelfelder, S., Schiele, F., Kreuz, S., Lamla, T., Müller, P., & Park, J. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158355 · Cited by 17
“Additional known co-receptors include hepatocyte growth factor receptor [17], CD9 [18], fibroblast growth factor recptor-1 [19], laminin receptor [20], and GPR108 [21].”
BackgroundSchüttrumpf, J., Zou, J., Zhang, Y., Schlachterman, A., Liu, Y.-L., Edmonson, S. A., Xiao, W., & Arruda, V. R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.004 · Cited by 19
Stiefelhagen, M., Sellner, L., Kleinschmidt, J. A., Jauch, A. S., Laufs, S., Wenz, F. K., Zeller, W. J., Früehauf, S., & Veldwijk, M. R. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-12 · Cited by 19
Watanabe, M. (2011) · Oncology Reports · doi:10.3892/or.2011.1371 · Cited by 18
“The construction and production of AAV vectors was performed as previously described (15-17).”
Self-citationViral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 19
Recombinant Adeno-Associated Virus: Efficient Transduction of the Rat VMH and Clearance from Blood
van Gestel, M. A., Boender, A. J., de Vrind, V. A. J., Garner, K. M., Luijendijk, M. C. M., & Adan, R. A. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097639 · Cited by 18
Hemphill, D. D., McIlwraith, C. W., Samulski, R. J., & Goodrich, L. R. (2014) · Scientific Reports · doi:10.1038/srep05861 · Cited by 18
Structural Study of Aavrh.10 Receptor and Antibody Interactions
Mietzsch, M., Yu, J. C., Hsi, J., Chipman, P. R., Broecker, F., Fuming, Z., Linhardt, R. J., Seeberger, P. H., Heilbronn, R., McKenna, R., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01249-21 · Cited by 16
“laminin (35), the hepatocyte growth factor receptor (36), the fibroblast growth factor receptor”
BackgroundHoad, M., Cross, E. M., Donnelly, C. M., Sarker, S., Roby, J. A., & Forwood, J. K. (2023) · Viruses · doi:10.3390/v15020315 · Cited by 15
“There are 13 recognized serotypes [6] and over 150 different variants of AAV, with many displaying specific tissue tropism [7] determined by the receptor binding of the AAV capsid with the cell surface [8].”
BackgroundOn the Search for Skin Gene Therapy Strategies of Xeroderma Pigmentosum Disease
Menck, C. F. M., Armelini, M. G., & Lima-Bessa, K. M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859017 · Cited by 18
“For example, AAV2 interaction with heparan sulfate proteoglycans is important for cell binding and transduction [Kashiwakura et al., 2005].”
BackgroundStrategies for Targeting Tumors and Tumor Vasculature for Cancer Therapy
Sreeramoju, P. V., & Libutti, S. K. (2010) · Advances in genetics · doi:10.1016/s0065-2660(10)69015-3 · Cited by 17
Xie, Q., Spilman, M. S., Meyer, N., Lerch, T. F., Stagg, S. M., & Chapman, M. S. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.09.004 · Cited by 17
“The corresponding residues in AAV-2 (Arg585 and Arg588) are among 5 positively charged residues in a region predicted to be involved from the crystal structure (Xie et al., 2002) and among those implicated in heparin binding and cell attachment by mutagenesis (Kern et al., 2003).”
BackgroundMethodInfluentialMacdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 17
N-glycomic profiling of capsid proteins from Adeno-Associated Virus serotypes
Xie, Y., & Butler, M. (2023) · Glycobiology · doi:10.1093/glycob/cwad074 · Cited by 16
Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
Meumann, N., Schmithals, C., Elenschneider, L., Hansen, T., Balakrishnan, A., Hu, Q., Hook, S., Schmitz, J., Bräsen, J. H., Franke, A., et al. (2022) · Cancers · doi:10.3390/cancers14020427 · Cited by 15
“In addition, HSPG-dependent accumulation of HGF and clathrin-dependent HGFR internalization and intracellular trafficking to the Golgi apparatus resemble AAV’s infectious pathway [54] and may enhance AAVs transduction efficiency.”
BackgroundHu, G., Silveria, M., Zane, G. M., Chapman, M. S., & Stagg, S. M. (2022) · Journal of Virology · doi:10.1128/jvi.00106-22 · Cited by 16
Role of Integrin Cross-Regulation in Parvovirus B19 Targeting
Weigel-Kelley, K. A., Yoder, M., Chen, L.-Y., & Srivastava, A. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.909 · Cited by 15
Large, E. E., & Chapman, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1116896 · Cited by 16
Lee, H., Shin, O. K., Kim, S., Lee, W. Y., Jeong-Yu, S., Park, K., Choe, H., & Lee, H. (2007) · Oncology Reports · doi:10.3892/or.18.3.611 · Cited by 14
Viral Gene Transfer to Developing Mouse Salivary Glands
Hsu, J. C., Pasquale, G. D., Harunaga, J. S., Onodera, T., Hoffman, M. P., Chiorini, J. A., & Yamada, K. M. (2011) · Journal of Dental Research · doi:10.1177/0022034511429346 · Cited by 14
“Additional proteins, including fibroblast growth factor receptor 1, αvβ5 integrin, and hepatocyte growth factor receptor, are involved in AAV2 transduction as well (Mizukami et al., 1996; Qing et al., 1999; Summerford et al., 1999; Kashiwakura et al., 2005).”
BackgroundFluorescence Microscopy in Adeno-Associated Virus Research
Golm, S. K., Hübner, W., & Müller, K. M. (2023) · Viruses · doi:10.3390/v15051174 · Cited by 12
“For the endocytosis of AAV2, several co-receptors were identified, such as the hepatocyte growth factor receptor (HGFR) [24], laminin receptor (LamR) [25], or integrins (α5β1 and αvβ5) [20,26].”
BackgroundAAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes
Chaqour, B., Duong, T. T., Yue, J., Liu, T., Camacho, D., Dine, K. E., Esteve-Rudd, J., Ellis, S., Bennett, J., Shindler, K. S., et al. (2024) · Gene Therapy · doi:10.1038/s41434-023-00436-8 · Cited by 12
“AAV2 uses heparan sulfate proteoglycan (HSPG) as its primary receptor [18], as well as other coreceptors including fi broblast growth factor receptor [19], hepatocyte growth factor receptor [20], integrins [21], and CD9 [22].”
Frisch, J., Orth, P., Venkatesan, J. K., Rey‐Rico, A., Schmitt, G., Kohn, D., Madry, H., & Cucchiarini, M. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0149 · Cited by 12
de Backer, M. W. A., Fitzsimons, C. P., Brans, M. A. D., Luijendijk, M. C. M., Garner, K. M., Vreugdenhil, E., & Adan, R. A. H. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-81 · Cited by 15
“To date, at least 12 serotypes of AAV are discovered (AAV1-AAV12) [11-20] that probably use different receptors to enter cells [21-28].”
BackgroundMessina, E., Nienaber, J. J., Daneshmand, M. A., Villamizar, N. R., Samulski, J. R., Milano, C. A., & Bowles, D. E. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.066 · Cited by 11
“Fibroblast growth factor receptor-1 (FGFR1), hepatocyte growth factor receptor (HGFR), avb5 integrin, and a5b1 integrin have all been implicated as coreceptors for AAV2 (Qing et al., 1999; Summerford et al., 1999; Kashiwakura et al., 2005; Asokan et al., 2006).”
BackgroundNovel vectors forin vivogene delivery to vascular tissue
White, K., Nicklin, S. A., & Baker, A. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.6.809 · Cited by 11
“It uses α v β 5 integrin [92] , fibroblast growth factor receptor type 1 [93] , hepatocyte growth factor receptor c-Met [94] or laminin receptor [95] as co-receptors to enable internalisation.”
MethodHoad, M., Roby, J. A., & Forwood, J. K. (2021) · FEBS Letters · doi:10.1002/1873-3468.14209 · Cited by 10
Recombinant Adeno-Associated Viral Vectors
de Backer, M. W. A., Garner, K. M., Luijendijk, M. C. M., & Adan, R. A. H. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-310-3_24 · Cited by 9
Belur, L. R., Kaemmerer, W. F., McIvor, R. S., & Low, W. C. (2008) · Archives of Virology · doi:10.1007/s00705-008-0222-7 · Cited by 10
Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery
Song, L., Bower, J. J., & Hirsch, M. L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0599-8_7 · Cited by 8
Adeno-associated virus for cystic fibrosis gene therapy
Martini, S. V., Rocco, P. R. M., & Morales, M. M. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500123 · Cited by 13
“Five receptors have been identified: αVβ5 integrin (42), fibroblast growth factor receptor 1 (43), hepatocyte growth factor receptor (44), αVβ1 integrin (45), and laminin receptor (46).”
BackgroundAugmented transgene expression in transformed cells using a parvoviral hybrid vector
Krüger, L., Eskerski, H., Dinsart, C., Cornelis, J. J., Rommelaere, J., Haberkorn, U., & Kleinschmidt, J. A. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701113 · Cited by 8
Engineering Baculo- and Lentiviral Vectors for Enhanced and Targeted Gene Delivery
Kaikkonen, M. U. (2008) · Cited by 8
Structural basis for nuclear import of bat adeno-associated virus capsid protein
Hoad, M., Roby, J. A., & Forwood, J. K. (2024) · Journal of General Virology · doi:10.1099/jgv.0.001960 · Cited by 7
“Moreover, AAVs can exhibit specific tissue tropism [11, 12], and the ease with which they can be adapted to different tropisms through genetic engineering [12–16] makes these viruses the most extensively researched therapeutic viral vector for gene therapy.”
BackgroundTabata, K., Sugano, E., Murakami, F., Yamashita, T., Ozaki, T., & Tomita, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.014 · Cited by 7
Mouland, A. J., Gatignol, A., & Heveker, N. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200500031 · Cited by 7
Rostami, M. R., Leopold, P. L., Vasquez, J. M., Rougvie, M. D. M., Al-Shakaki, A., Hssain, A. A., Robay, A., Hackett, N. R., Mezey, J. G., & Crystal, R. G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101136 · Cited by 5
Pipatpadungsin, N., Chao, K., & Rouse, S. L. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03087 · Cited by 7
AAVR Expression is Essential for AAV Vector Transduction in Sensory Hair Cells
Wu, F., Chen, G., Hu, R., Liu, P., Lou, J., Zhao, W., He, Z., Sha, S., & Zheng, Y. (2025) · Advanced Science · doi:10.1002/advs.202408873 · Cited by 6
Wong, F. F., Ho, M. L., Yamagami, M., Lam, M. T., Grande-Allen, K. J., & Suh, J. (2015) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2014.0493 · Cited by 6
“32 AAV2 and AAV3 are reported to bind the same co-receptors, including human fibroblast growth factor receptor, 33,34 hepatocyte growth factor receptor, 35,36 and laminin receptor.”
Reverse transduction can improve efficiency of AAV vectors in transduction‐resistant cells
Lee, E. J., Robinson, T. M., Tabor, J. J., Mikos, A. G., & Suh, J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26830 · Cited by 6
Rajapaksha, I. G., Angus, P., & Herath, C. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80317 · Cited by 5
“AAV9 interacts with N-terminal galactose as the primary receptor [21] and also interacts with secondary coreceptors for facilitating cell entry, such as integrins [15, 22] FGFR1 [16], hepatocyte growth factor receptor (c-Met) [23], and laminin receptor [24].”
BackgroundUtility of AAV Vectors Derived from Novel Serotypes
Mizukami, H., & Ozawa, K. (2006) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.126.1021 · Cited by 4
Cui, M., Zhao, Q., Wang, J., Si, Y., Cheng, S., & Ding, W. (2021) · Journal of Virology · doi:10.1128/jvi.01103-21 · Cited by 4
“ceptors to promote viral infection (8, 9).”
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Fusion of Anthopleurin-B to AAV2 increases specificity of cardiac gene transfer
Finet, J. E., Wan, X., & Donahue, J. K. (2017) · Virology · doi:10.1016/j.virol.2017.10.006 · Cited by 4
Gene therapy using AAV vectors
Ozawa, K. (2007) · Drug Delivery System · doi:10.2745/dds.22.643 · Cited by 4
Cho, I.-R., Kaowinn, S., Song, J., Kim, S., Koh, S. S., Kang, H.-Y., Ha, N., Lee, K. H., Jun, H.-S., & Chung, Y.-H. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.17 · Cited by 4
RetractedUsing Recombinant Adeno-Associated Viral Vectors for Gene Expression in the Brain
der Perren, A. V., Toelen, J., Taymans, J., & Baekelandt, V. (2011) · Neuromethods · doi:10.1007/978-1-61779-533-6_3 · Cited by 4
Tripathi, S., Huda, S., Kar, J., Chandra, D., Jayandharan, G. R., & Mohan, N. (2025) · Journal of Cell Science · doi:10.1242/jcs.264190 · Cited by 3
“Mechanistically AAV2 enters cells via heparan sulfate proteoglycan (HSPG)-mediated endocytosis with growth factor receptors acting as co-receptors (Kashiwakura et al., 2005; Qing et al., 1999; Summerford and Samulski, 1998; Weller et al., 2010).”
AAV Serotypes and Their Suitability for Retinal Gene Therapy
Ebner, L. J. A., & Grimm, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-27681-1_20 · Cited by 3
Ito, K., Ookawara, S., Ishibashi, K., & Morishita, Y. (2017) · Nano Reviews & Experiments · doi:10.1080/20022727.2017.1341758 · Cited by 3
Clathrin-Associated Endocytosis as a Route of Entry into Cells for Parvoviruses
Brent, F., & Dudleenamjil, E. (2012) · InTech eBooks · doi:10.5772/48510 · Cited by 2
“…& Samulski, 1998), and other cell entry receptors or co-receptors for AAV-2 include human fibroblast growth factor receptor-1 (FGFR-1) (Qing et al., 1999), αVβ5 integrin (Sanlioglu et al., 2000; Summerford et al., 1999), and hepatocyte growth factor receptor (c-Met) (Kashiwakura et al., 2005).”
BackgroundOzawa, K. (2007) · Uirusu · doi:10.2222/jsv.57.47 · Cited by 3
Viral Vectors for Gene Delivery
Dismuke, D. J., Gray, S. J., Hirsch, M. L., Samulski, R. J., & Muzyczka, N. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732239-00338 · Cited by 3
Antipova, A. Y., & Lavrentieva, I. N. (2017) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-2017-1-7-20 · Cited by 3
Hu, G., Silveria, M., Chapman, M. S., & Stagg, S. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.10.475736 · Cited by 3
Adeno-Associated Virus and AAV Vectors for Gene Delivery
Carter, B. (2015) · CRC Press eBooks · doi:10.1201/b18002-6 · Cited by 3
Nash, K. R., Cárdenas‐Aguayo, M. D. C., Berg, M. J., & Marks, N. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.008 · Cited by 2
Gene Delivery and Gene Therapy for Alzheimer’s Disease
Woodbury, M. E., Kiyota, T., & Ikezu, T. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_4 · Cited by 2
Bio-Production of Adeno-Associated Virus for Gene Therapy
Donohue, N., Keogh, N., Boi, S., & Barron, N. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_11 · Cited by 1
Yahata, T., Toujima, S., Sasaki, I., Iwahashi, N., Fujino, M., Nishioka, K., Noguchi, T., Tanizaki-Horiuchi, Y., Kaisho, T., & Ino, K. (2025) · BMC Cancer · doi:10.1186/s12885-025-14093-0 · Cited by 1
“Immunohistochemical analyses and tumor-infiltrating lymphocyte profiling were performed to elucidate the mechanism by which intraperitoneal injection of PD-L1 AAV particles for 9 times on days 3, 10, 17, 24, 31, 38, 45, 52 and 59 was repeated every week that suppressed ovarian cancer progression.”
Nonenveloped Capsid: Mechanisms of Viral Entry
Lins, B., & Agbandje‐McKenna, M. (2014) · Future Virology · doi:10.2217/fvl.14.82 · Cited by 1
The Use of Viral Vectors to Enhance Cognition
Ikezu, T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00006-1 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Viral vectors for gene therapy
Tsai, A., Suzuki‐Hatano, S., & Pacak, C. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00019-8 · Cited by 2
[Serotypes of adeno-associated viruses].
Lipiec, A., Małecki, M., & Hajdukiewicz, K. (2009) · PubMed · Cited by 5
Viral infection: A key host receptor for AAV
Sun, S., & Schaffer, D. V. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.27 · Cited by 1
New innovations for ocular gene therapy
Igarashi, T., Miyake, K., Kobayashi, M., Takahashi, K., Nakamoto, K., Okada, T., & Takahashi, H. (2017) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.13.88 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
New strategies for the application of Adeno-Associated Virus type 2 targeting vectors
Goldnau, D. (2006) · doi:10.5282/edoc.7345 · Cited by 1
Chaurette, J. (2013) · doi:10.13028/m2930z
“binds to one or more specific cell surface molecules: sialic acid for AAV1, heparin sulfate proteoglycan for AAV2, laminin receptor for AAV8, and galactose for AAV9 [285-288].”
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Belhoul‐Fakir, H. (2014) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17008231.v1
Expanding AAV cargo capacity for gene therapy of Stargardt disease
Trapani, I. (2014)
Metadata
- Authors
- Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H.
- Affiliations
- Juntendo University (JP)
- Nippon Medical School (JP)
- The University of Osaka (JP)
- Okayama University (JP)
- Departments of Cardiology
- Corresponding author
- Tamayose, Kenji
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2005-01
- Volume
- 79
- Issue
- 1
- Pages
- 609-614
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC538679
- OpenAlex
- W2120683337
- Cited by
- 246
- References
- 37
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 16 · 2020: 10 · 2019: 12 · 2018: 8 · 2017: 13 · 2016: 9 · 2015: 15 · 2014: 8 · 2013: 13 · 2012: 12
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus type 2, c-Met, co-receptors, viral entry, heparan sulfate proteoglycans, integrin αvβ5, FGFR1, transgene expression, viral internalization, receptor interaction
- MeSH terms
- Dependovirus, Animals, Cricetinae, HeLa Cells, Humans, Receptors, Virus, Transduction, Genetic, CHO Cells, 3T3 Cells, Hepatocyte Growth Factor, Proto-Oncogene Proteins c-met, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
